Antibody drug conjugates combine monoclonal antibodies with highly potent anti-cancer payloads through chemical linkers. The monoclonal antibodies enable targeted delivery of the attached drug payload to cancerous cells. Major applications of antibody drug conjugates include breast cancer, lung cancer, lymphoma and others.

The global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn in 2023 and is expected to exhibit a CAGR of 14 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Rising prevalence of cancer across the globe is expected to be a key driver for growth of the antibody drug conjugates market over the forecast period. According to World Health Organization (WHO), cancer is the second leading cause of death globally and accounted for nearly 10 million deaths in 2020. Breast cancer is the most common type of cancer in women worldwide. Growing geriatric population is another factor fueling growth of the market as risk of cancer increases with age. Furthermore, continuous research and development activities for development of innovative antibody drug conjugates to treat various types of cancer is also expected to boost market growth during the forecast period.

SWOT Analysis

Strength:
- Increasing prevalence of cancer worldwide is driving the demand for ADC drugs
- Continuous R&D in developing safer and more effective ADC drugs
- Availability of various monoclonal antibodies and cytotoxic agents for conjugate development

Weakness:
- Complex manufacturing process increases production costs of ADC drugs
- Challenges in developing stable drug-linker conjugates

Opportunity:
- Emerging applications of ADC drugs in treatment of autoimmune diseases and infectious diseases
- Untapped growth potential in developing economies provides market expansion opportunities

Threats:
- Stiff competition from conventional cancer treatment therapeutics
- Potential side effects and safety issues related to ADC drugs limits their adoption

Key Takeaways

The global Antibody Drug Conjugates Market size is expected to witness high growth, exhibiting 14% CAGR over the forecast period, due to increasing prevalence of cancer worldwide. The global market size for Antibody Drug Conjugates is estimated to reach US$ 5.38 Billion by 2023.

Regional analysis:
North America dominates the global ADC market currently due to strong research infrastructure and increasing funding for development of advanced cancer therapeutics. Asia Pacific is projected to exhibit fastest growth in the upcoming years supported by rising healthcare expenditures and growing cancer burden in the region.

Key players analysis:
Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.